Molecular testing system developer Isoma was spun out from Wistar but has also licensed intellectual property from University of Pennsylvania.
Isoma Diagnostics, a US-based molecular testing spinout from biomedical research centre Wistar, has obtained an undisclosed amount of seed capital from investors including regional commercialisation alliance University City Science Center.
A spokesperson for Wistar Institute told Genome Web the deal had raised a six-figure dollar sum.
Seed fund Ben Franklin Technology Partners also took part in the round. University City Science Center invested through its Phase I Ventures program, which provides patient capital in sectors such as biotech and pharmaceuticals.
…
